Results 131 to 140 of about 19,163 (327)

Self‐Management Therapies for Temporomandibular Disorders—Evidence From Systematic Reviews

open access: yesJournal of Oral Rehabilitation, EarlyView.
This umbrella review synthesized existing evidence on self‐management therapy for temporomandibular disorder. ABSTRACT Objectives Chronic pain in the orofacial region affects 10%–15% of the general population. It is most often related to temporomandibular disorders (TMD): pain in the masticatory muscles and the temporomandibular joints.
Tessa Bijelic   +5 more
wiley   +1 more source

Pharmacological properties and SAR of new 1,4-disubstituted piperazine derivatives with hypnotic-sedative activity [PDF]

open access: bronze, 2002
Zdzisław Chilmończyk   +6 more
openalex   +1 more source

Chronic insomnia, REM sleep instability and emotional dysregulation: A pathway to anxiety and depression?

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary The world‐wide prevalence of insomnia disorder reaches up to 10% of the adult population. Women are more often afflicted than men, and insomnia disorder is a risk factor for somatic and mental illness, especially depression and anxiety disorders.
Dieter Riemann   +13 more
wiley   +1 more source

Synthesis and hypnotic-sedative activities of N-substituted uracil on mice [PDF]

open access: bronze, 2003
Takahiro Maruyama   +5 more
openalex   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

Respiratory safety of lemborexant in adult and elderly subjects with moderate‐to‐severe chronic obstructive pulmonary disease

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Lemborexant 10 mg, a dual orexin‐receptor antagonist (DORA), did not elicit respiratory depressant effects, as measured by peripheral oxygen saturation (SpO2) or apnea–hypopnea index (AHI), in subjects with moderate‐to‐severe chronic obstructive pulmonary disease (COPD).
Jocelyn Y. Cheng   +3 more
wiley   +1 more source

Acupuncture for persistent insomnia associated with major depressive disorder: a randomised controlled trial [PDF]

open access: yes, 2016
published_or_final_versio
Chan, KW   +6 more
core  

A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia

open access: yesJournal of Sleep Research, EarlyView.
Summary This double‐blind, placebo‐controlled, two‐way crossover trial evaluated the efficacy and safety of daridorexant in patients with chronic insomnia and comorbid nocturia. In total, 60 patients aged ≥55 years with insomnia complaints for ≥3 months, Insomnia Severity Index (ISI) ≥13 and ≥3 voids/night for ≥1 month were randomised (1:1) to ...
Katharina Lederer   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy